Prognostic value of circulating VEGFR2 + bone marrow-derived progenitor cells in patients with advanced cancer

European Journal of Cancer

Volumn 48, Issue 9, 2012, Pages 1354-1362

  Massard, Christophe ^a   Borget, Isabelle ^a   Deley, Marie Cécile Le ^a   Taylor, Melissa ^a   Gomez Roca, Carlos ^a   Soria, Jean Charles ^a   Farace, Françoise ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Advanced cancers; Angiogenesis biomarker; Circulating bone marrow derived progenitor cells; Circulating endothelial cells; Prognosis

Indexed keywords

ANGIOGENESIS INHIBITOR; CD146 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; VASCULAR TARGETING AGENT; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; AGGRESSIVENESS; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; FATALITY; FEMALE; FLOW CYTOMETRY; HAZARD RATIO; HEMATOPOIETIC STEM CELL; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RATING SCALE; ROYAL MARSDEN HOSPITAL SCORE; TUMOR EMBOLISM;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BONE MARROW; CLINICAL TRIALS, PHASE I AS TOPIC; ENDOTHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; STEM CELLS; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84861330308     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.01.021     Document Type: Article

References (34)

1. M. Seandel, J. Butler, D. Lyden, and S. Rafii A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization Cancer Cell 13 2008 181 183
2. M.C. Yoder, and D.A. Ingram Endothelial progenitor cell: ongoing controversy for defining these cells and their role in neoangiogenesis in the murine system Curr Opin Hematol 16 2009 269 273
3. S. Purhonen, J. Palm, and D. Rossi Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth Proc Natl Acad Sci USA 105 2008 6620 6625
4. D. Lyden, K. Hattori, and S. Dias Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth Nat Med 7 2001 1194 1201
5. D.J. Nolan, A. Ciarrocchi, and A.S. Mellick Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization Genes Dev 21 2007 1546 1558
6. D. Gao, D.J. Nolan, and A.S. Mellick Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis Science 319 5860 2008 195 198
7. A.D. Blann, A. Woywodt, and F. Bertolini Circulating endothelial cells. Biomarker of vascular disease Thromb Haemost 93 2005 228 235
8. N. Jacques, N. Vimond, and R. Conforti Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay J Immunol Methods 337 2008 132 143
9. P.K. Goon, C.J. Boos, P.S. Stonelake, A.D. Blann, and G.Y. Lip Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison Thromb Haemost 96 2006 45 52
10. P.M. LoRusso, S.A. Boerner, and L. Seymour An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics Clin Cancer Res 16 2010 1710 1718
11. E.X. Chen, and I.F. Tannock Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation JAMA 292 2004 2150 2151
12. T.G. Roberts Jr, B.H. Goulart, and L. Squitieri Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials JAMA 292 2004 2130 2140
13. T. Bachelot, I. Ray-Coquard, and G. Catimel Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials Ann Oncol 11 2000 151 156
14. A. Italiano, C. Massard, and R. Bahleda Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy Ann Oncol 19 2008 787 792
15. C. Han, J.P. Braybrooke, and G. Deplanque Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents Br J Cancer 89 2003 1166 1171
16. J. Wheler, A.M. Tsimberidou, and D. Hong Survival of patients in a phase 1 clinic: the M.D. Anderson cancer center experience Cancer 115 2009 1091 1099
17. N. Penel, M. Vanseymortier, and M.E. Bonneterre Prognostic factors among cancer patients with good performance status screened for phase I trials Invest New Drugs 26 2008 53 58
18. H.T. Arkenau, J. Barriuso, and D. Olmos Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2009 2692 2696
19. F. Farace, C. Massard, and E. Borghi Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells Ann Oncol 18 2007 1421 1422
20. M. Taylor, J. Rössler, and B. Geoerger High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies Clin Cancer Res 15 2009 4561 4571
21. F. Farace, M. Gross-Goupil, and E. Tournay Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors Br J Cancer 104 2011 1144 1150
22. D. Malka, V. Boige, and N. Jacques Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab Ann Oncol 2011
23. D. Olmos, R.D. Baird, and T.A. Yap Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials Clin Cancer Res 17 11 2011 1 9
24. Y. Shaked, E. Henke, and J.M. Roodhart Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents Cancer Cell 14 2008 263 273
25. F. Andre, S. Delaloge, and J.C. Soria Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 2011
26. C.P. Carden, D. Sarker, and S. Postel-Vinay Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today 15 2010 88 97
27. T.A. Yap, S.K. Sandhu, P. Workman, and J.S. de Bono Envisioning the future of early anticancer drug development Nat Rev Cancer 10 2010 514 523
28. A.M. Jubb, A.J. Oates, S. Holden, and H. Koeppen Predicting benefit from anti-angiogenic agents in malignancy Nat Rev Cancer 6 2006 626 635
29. F. Bertolini, Y. Shaked, P. Mancuso, and R.S. Kerbel The multifaceted circulating endothelial cell in cancer: towards marker and target identification Nat Rev Cancer 6 2006 835 845
30. L. Vroling, J.S. Lind, and R.R. de Haas CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients Br J Cancer 102 2010 268 275
31. A.X. Zhu, D.V. Sahani, and D.G. Duda Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 2009 3027 3035
32. M.H. Strijbos, J. Kraan, and M.A. den Bakker Cells meeting our immunophenotypic criteria of endothelial cells are large platelets Cytometry B Clin Cytom 72 2007 86 93
33. M.H. Strijbos, J.W. Gratama, and J. Kraan Circulating endothelial cells in oncology: pitfalls and promises Br J Cancer 98 2008 1731 1735
34. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603